Morning Overview on MSN
A year of added prostate-cancer therapy cut the odds the disease spreads, a major trial found
Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two full years alongside radiation can meaningfully reduce the chance the ...
WASHINGTON — Former President Joe Biden is receiving radiation and hormone therapy as part of a new phase of treating the aggressive form of prostate cancer he was diagnosed with after leaving office, ...
First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital ...
SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
Former President Joe Biden is now receiving radiation and hormone therapy as part of his ongoing treatment for prostate cancer, a spokesperson said Saturday. The nation’s 46th president was diagnosed ...
SAN FRANCISCO -- Adding hormone therapy to postoperative radiotherapy did not improve overall survival (OS) for most men with prostate cancer, according to a meta-analysis of individual patient data.
In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...
After 6 months of hormone therapy, men with prostate cancer showed worsening lipid profiles, with 21% showing increased risk of cardiovascular disease based on general population tools. Men receiving ...
Study flowchart of patient selection: Inclusion and exclusion criteria. ED, erectile dysfunction; EDITS, Erectile Dysfunction Inventory of Treatment Satisfaction; RCP, radical cystoprostatectomy; RP, ...
Akeega prostate cancer UK approval: the MHRA has licensed Johnson and Johnson's niraparib-abiraterone combination for men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results